Novartis Pharma AG Sustainability Profile
Novartis Pharma AG, commonly referred to as Novartis, is a leading global healthcare company headquartered in Switzerland (CH). Founded in 1996 through the merger of Ciba-Geigy and Sandoz, Novartis has established a strong presence in key operational regions, including North America, Europe, and Asia. Specialising in innovative pharmaceuticals and generics, Novartis focuses on areas such as oncology, cardiology, immunology, and neuroscience. The company is renowned for its commitment to research and development, producing unique therapies that address unmet medical needs. With a robust portfolio of patented medications and a significant market position, Novartis has achieved numerous accolades, including recognition for its contributions to advancing healthcare and improving patient outcomes worldwide.
DitchCarbon Score
How does Novartis Pharma AG's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Novartis Pharma AG's score of 100 is higher than 99% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
As of the latest available data, Novartis Pharma AG does not report specific carbon emissions figures, indicating a lack of detailed emissions data for the most recent year. However, it is important to note that Novartis Pharma AG is a current subsidiary of Novartis AG, which may influence its climate commitments and reporting. Novartis AG has established various climate initiatives and commitments that cascade down to its subsidiaries, including Novartis Pharma AG. These initiatives include participation in the Science Based Targets initiative (SBTi), the Carbon Disclosure Project (CDP), and the RE100 initiative, all aimed at enhancing sustainability and reducing carbon footprints across their operations. While specific reduction targets for Novartis Pharma AG are not detailed, the overarching commitments from Novartis AG suggest a strategic focus on climate action and emissions reduction. The company is actively engaged in efforts to align with global climate goals, although specific metrics and targets for Novartis Pharma AG remain unspecified. In summary, while Novartis Pharma AG currently lacks specific emissions data, it benefits from the climate commitments and initiatives of its parent company, Novartis AG, which are designed to drive sustainability and reduce carbon emissions across its operations.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 583,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 922,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - | 000,000,000 | 000,000,000 | 000,000,000 | - | 0,000,000,000 | 0,000,000,000 | 000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 |
How Carbon Intensive is Novartis Pharma AG's Industry?
How Carbon Intensive is Novartis Pharma AG's Location?
Novartis Pharma AG's Scope 3 Categories Breakdown
Novartis Pharma AG's Scope 3 emissions, which decreased by 5% last year and increased significantly since 2013, demonstrating supply chain emissions tracking. Nearly all of their carbon footprint comes from suppliers and value chain emissions, representing nearly all emissions under the GHG Protocol, with "Purchased Goods and Services" being the largest emissions source at 78% of Scope 3 emissions.
Top Scope 3 Categories
Novartis Pharma AG's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Novartis Pharma AG has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
